Skip to main content
. 2021 Feb 10;5(3):e532. doi: 10.1097/HS9.0000000000000532

Figure 3.

Figure 3.

Outcome according to BMI difference between diagnosis and allogeneic HSCT (ΔBMI >2 vs ≤ –2) in AML patients receiving allogeneic HSCT (n = 369). (A) Nonrelapse mortality and (B) overall survival. AML = acute myeloid leukemia; BMI = body mass index; HSCT = hematopoietic stem cell transplantation.